Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per-Anders Abrahamsson

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
European Urology|July 26, 2005
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general populationYvonne L Giwercman, Per-Anders Abrahamsson, Aleksander Giwercman, et al.
BJU International|January 18, 2014
Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?Johannes M Wolff, Per-Anders Abrahamsson, Jacques Irani, et al.
European Urology|December 7, 2007
The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostateJens A Ceder, Linda Jansson, Roy A Ehrnström, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 17, 2010
Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse modelCamilla Cervin, Martina Tinzl, Markus Johnsson, et al.
Scandinavian Journal of Urology and Nephrology|October 22, 2010
PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient populationMartin Nyberg, David Ulmert, Anna Lindgren, et al.
The Prostate|June 15, 2011
Regional distribution of neuroendocrine cells in the urogenital duct system of the male ratGerhard Aumüller, Andreas Doll, Gunther Wennemuth, et al.
Plos One|November 22, 2013
Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancerMartina Tinzl, Binshen Chen, Shao-Yong Chen, et al.
Plos One|December 19, 2018
Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate CancerMartina Tinzl, Binshen Chen, Shao-Yong Chen, et al.
The Prostate|March 26, 2004
Androgen receptor CAG repeat length correlates with semen PSA levels in adolescenceYvonne Lundberg Giwercman, Jonas Richthoff, Hans Lilja, et al.
Urologic Oncology|November 21, 2009
Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell linesNishtman Dizeyi, Petter Hedlund, Anders Bjartell, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
European Urology|July 26, 2005
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general populationYvonne L Giwercman, Per-Anders Abrahamsson, Aleksander Giwercman, et al.
BJU International|January 18, 2014
Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?Johannes M Wolff, Per-Anders Abrahamsson, Jacques Irani, et al.
European Urology|December 7, 2007
The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostateJens A Ceder, Linda Jansson, Roy A Ehrnström, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 17, 2010
Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse modelCamilla Cervin, Martina Tinzl, Markus Johnsson, et al.
Scandinavian Journal of Urology and Nephrology|October 22, 2010
PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient populationMartin Nyberg, David Ulmert, Anna Lindgren, et al.
The Prostate|June 15, 2011
Regional distribution of neuroendocrine cells in the urogenital duct system of the male ratGerhard Aumüller, Andreas Doll, Gunther Wennemuth, et al.
Plos One|November 22, 2013
Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancerMartina Tinzl, Binshen Chen, Shao-Yong Chen, et al.
Plos One|December 19, 2018
Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate CancerMartina Tinzl, Binshen Chen, Shao-Yong Chen, et al.
The Prostate|March 26, 2004
Androgen receptor CAG repeat length correlates with semen PSA levels in adolescenceYvonne Lundberg Giwercman, Jonas Richthoff, Hans Lilja, et al.
Urologic Oncology|November 21, 2009
Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell linesNishtman Dizeyi, Petter Hedlund, Anders Bjartell, et al.
Pageof 6